Cheryl Q. Xu

Managing Director, Hope Center for National Health Studies- Beijing University

Cheryl’s past positions included Director of International Finance at Pharmacia (merged with Pfizer) in New Jersey. She was later in charge of Pharmacia’s Business Development in Asia & Latin America. She co-led Pharmacia’s restructuring projects in Argentina and China during the previous financial crisis.

After 14 years in the U.S., Cheryl returned to Beijing as the first PhRMA Representative in China. She represented the industry to work with the Chinese government on key issues such as pricing, reimbursement and IPR.

In 2005, she started her consulting business, advising some of the well-known multinational companies (for example: JNJ, Pfizer, Merck, BMS, Bausch & Lomb, Schering Plough, Novo Nordisk, UnitedHealth Group and others), on their market access and expansion strategies in China. Activities include new product launches, M&A transactions and public affair events such as anti-monopoly investigations. She also advises some U.S. investment funds.

Cheryl provides consultations to both the U.S. and Chinese governments on pharmaceutical policies. She directly contributed to the formulations of China’s healthcare reform policies published in 2009. She also works with charity projects related to public health, especially in areas of mental health (including dementia). She founded and serves as Director, Hope Center for National Health Studies in Beijing.

Cheryl received her Bachelor of Science degree in Physics from Peking University, and MBA in Finance from Washington University in St. Louis.

Cheryl Q. Xu

Managing Director, Hope Center for National Health Studies- Beijing University

Cheryl’s past positions included Director of International Finance at Pharmacia (merged with Pfizer) in New Jersey. She was later in charge of Pharmacia’s Business Development in Asia & Latin America. She co-led Pharmacia’s restructuring projects in Argentina and China during the previous financial crisis.

After 14 years in the U.S., Cheryl returned to Beijing as the first PhRMA Representative in China. She represented the industry to work with the Chinese government on key issues such as pricing, reimbursement and IPR.

In 2005, she started her consulting business, advising some of the well-known multinational companies (for example: JNJ, Pfizer, Merck, BMS, Bausch & Lomb, Schering Plough, Novo Nordisk, UnitedHealth Group and others), on their market access and expansion strategies in China. Activities include new product launches, M&A transactions and public affair events such as anti-monopoly investigations. She also advises some U.S. investment funds.

Cheryl provides consultations to both the U.S. and Chinese governments on pharmaceutical policies. She directly contributed to the formulations of China’s healthcare reform policies published in 2009. She also works with charity projects related to public health, especially in areas of mental health (including dementia). She founded and serves as Director, Hope Center for National Health Studies in Beijing.

Cheryl received her Bachelor of Science degree in Physics from Peking University, and MBA in Finance from Washington University in St. Louis.